Method for treating heart failure with preserved ejection fraction by administering human relaxin-2
View Patent ↗A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.
1. A method of treatment of a subject afflicted of a chronic heart failure with preserved ejection fraction (HFPEF) and stiffening of the heart muscle together with a deficient phosphorylation of a cardiospecific titin, comprising an administration of a pharmaceutical composition comprising human relaxin-2molecules capable of binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase heart compliance and stroke volume and to lower the end-diastolic pressure of the left ventricle.
2. The method of claim 1 for treating the effects of a hypophosphorylation of the cardiospecific titin N2B.
3. The method of claim 1 , wherein the pharmaceutical composition comprises the human relaxin-2 molecules in admixture with a pharmaceutically acceptable adjuvant, carrier, diluent or excipient for subcutaeneous application.
4. The method of claim 1 , wherein the pharmaceutical composition is formulated as an emulsion (oil-in-water or water-in-oil) for delivery to the oral or gastrointestinal tract mucosa.
5. The method of claim 1 , wherein the pharmaceutical composition comprises a delivery vehicle selected from among a micelle, inverse micelle, liposome, cubosome and a mixture thereof.
6. The method of claim 1 , wherein the pharmaceutical composition comprises a mucoadhesive protein which is associated with the delivery vehicle via a chemical or physical bond, so that the composition adsorbs to the mucosa or is retained on a mucosal surface for effecting systemic delivery of the relaxin.
7. The method of claim 1 , wherein said composition is for subcutaneous infusion administering human relaxin-2 at a rate in the range of 10 μg/kg/day to 1000 μg/kg/day.
8. The method of claim 7 , wherein human relaxin-2 is administered at an infusion rate in the range of 30 μg/kg/day to 100 μg/kg/day.
9. The method of claim 1 , wherein said subject is further renally impaired.
10. The method of claim 1 , wherein said subject has a creatinine clearance in the range of 30 to 75 mL/min/1.73 m 2 .